GlassScriptPhysician profile
John Guerriero
NPI 1952525958
$11,951.15
in general payments reported to CMS, 2019-2025
38 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $350 · 2021: $287 · 2022: $1,465 · 2023: $4,102 · 2024: $2,426 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,933 · Travel and Lodging: $2,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,933.00 |
| Travel and Lodging | $2,971.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,533.67 | 2021-2025 | Ellipsys Vascular Access System, Symplicity G3, Venaseal |
| Boston Scientific Corporation | $1,310.74 | 2019-2024 | Eluvia, Varithena Administration Pack, Charger |
| Philips North America LLC | $1,296.10 | 2023 | |
| Mozarc Medical US LLC | $1,061.83 | 2023 | Argyle |
| Lumenis Be INC | $981.04 | 2025 | M22 |
| Smith+Nephew, INC. | $976.41 | 2019-2025 | Grafix Pl, Stravix Pl, Oasis |
| Organogenesis INC. | $762.82 | 2019-2025 | Affinity, Cygnus Dual, Puraply |
| Bolton Medical INC | $593.59 | 2022-2023 | Treo Abdominal Stent-Graft System, Relay Thoracic Stent-Graft With Plus Delivery System |
| Janssen Pharmaceuticals, INC | $404.47 | 2019-2023 | Spravato, Xarelto |
| Bioventus LLC | $255.28 | 2023 | Stimrouter Implantable Kit |
| Endologix LLC | $232.79 | 2019-2025 | Endocross Device, Torus Stent Graft System |
| Novo Nordisk INC | $209.28 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $163.18 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Convatec INC. | $139.66 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $137.56 | 2022-2025 | Nuzyra |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $125.71 | 2024 | Voquezna |
| Cordis US Corp. | $100.29 | 2023-2025 | Rain Sheath Transradial, Mynx Control Venous |
| Celularity INC. | $83.00 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.61 | 2024-2025 | Caplyta |
| Amarin Pharma, INC. | $52.95 | 2019 | |
| Progenacare Global, LLC | $52.40 | 2023 | |
| Bard Peripheral Vascular, INC. | $45.13 | 2019-2024 | Venclose Maven Catheter |
| Tactile Systems Technology INC | $37.19 | 2025 | Flexitouch Plus, Nimbl |
| Silk Road Medical, INC. | $35.50 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Reapplix INC. | $31.98 | 2024 | 3c Patch Kit - Box |
| Alk-Abello, INC | $30.64 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Teva Pharmaceuticals USA, INC. | $28.78 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lifenet Health | $25.43 | 2024 | Theragenesis Wound Matrix |
| Medtronic Vascular, INC. | $19.09 | 2020 | |
| Axonics, INC. | $19.06 | 2023 | Axonics |
| Kowa Pharmaceuticals America, INC. | $18.71 | 2023 | Seglentis |
| Glaxosmithkline, LLC. | $18.52 | 2023 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $18.10 | 2024 | Fanapt |
| Galderma Laboratories, L.P. | $17.39 | 2021 | |
| Pfizer INC. | $15.68 | 2025 | |
| Abbvie INC. | $15.25 | 2025 | |
| Cashflow Solutions, LLC | $14.63 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Lemaitre Vascular, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Guerriero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.